BUSINESS

• “Regulatory Science Center” to Play Important Role to Establish Next-Generation Treatments: JPMA President
  September 13, 2016

• Novartis Paid 13.2 Billion Yen to Doctors, Medical Institutions in 2015
  September 13, 2016

• Nippon Shinyaku on Track to Achieve Targets in Midterm Plan with Sales of Selexipag Above Expectations: President
  September 12, 2016

• Sales of Ethical Drugs Down 6.4% in July: Crecon Report
  September 12, 2016

• Takeda Starts Global PIII for Dengue Vaccine
  September 9, 2016

• Aspen Japan Launches Paxil AG
  September 9, 2016

• Ono Files Kyprolis for Multiple Myeloma as Combo Therapy with Dexamethasone
  September 8, 2016

• Ono Rolls out Multiple Myeloma Treatment Kyprolis
  September 8, 2016

• Biogen Japan’s Hemophilia Spinoff to Be Up and Running in Early 2017
  September 8, 2016

• Sun Taps Mitsubishi Tanabe to Distribute Novartis’ 14 Established Brands
  September 7, 2016

• Psoriasis Treatment Apremilast Achieves Primary Endpoint in Japan PIIb Trial: Celgene
  September 7, 2016

• BIKEN, Kaketsuken to Develop Zika Virus Vaccines from Strain Isolated by Chiba Prefectural Institute of Public Health
  September 7, 2016

• Mitsubishi Tanabe Applies for Partial Change to Remicade Dosage to Shorten Administration Interval in Crohn’s Disease
  September 7, 2016

• Fujifilm Gets 10%-plus Stake in Australian Cell Therapy Startup
  September 6, 2016

• Sato, Fuso to Copromote Emla Cream for Dialysis Patients
  September 6, 2016

• Hisamitsu Starts PIII Trial of Transdermal Schizophrenia Treatment in US
  September 6, 2016

• Celgene Seeks Japan Approval of Romidepsin for PTCL
  September 6, 2016

• Merck Ditches Osteoporosis Med Odanacatib from Global Pipelines
  September 6, 2016

• Sanofi’s PCSK9 Inhibitor Praluent Now Available in Japan
  September 6, 2016

• Shionogi Takes Osaka Tax Bureau to Court
  September 5, 2016

ページ

• « 先頭
• ‹ Prev
• …
• 458
• 459
• 460
• 461
• 462
• 463
• 464
• 465
• 466
• …
• Next ›
• 最終 »